Clinical Trial Detail

NCT ID NCT04273139
Title Ibrutinib + Venetoclax in Untreated WM
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

Waldenstroem's macroglobulinemia

Therapies

Ibrutinib + Venetoclax

Age Groups: senior adult

Additional content available in CKB BOOST